Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus
AssigneesWyeth, ViroPharma Incorporated
InventorsAriamala Gopalsamy, John W. Ellingboe, Tarek S. Mansour, Stephen M. Condon, Matthew G. Laporte, Christopher J. Burns, Kaapjoo Park, Marc S. Collett
Life of this patent
Estimating the term…
Abstract
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula: 1 Wherein substitutions at R1, R2 , R3-R12, and Y are set forth in the specification.
Claims126
A method of treating or preventing a Hepatitis C viral infection in a mammal comprising providing the mammal with an effective amount of a compound of a formula:
- 22
- R1 is H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl or an alkylaryl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl or alkylaryl of 7 to 12 carbon atoms, a cyanoalkyl of 1 to 8 carbon atoms, an alkylthioalkyl of 2 to 16 carbon atoms, a cycloalkyl-alkyl of 4 to 24 carbon atoms, a substituted or unsubstituted aryl, or a heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbons atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenylalkynyl, alkoxy of 1 to 8 carbon atoms, arylalkoxy of 7 to 12 carbon atoms, fluoroalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 8 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, acyl of 1 to 6 carbon atoms, COOH, COO-alkyl, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, alkylsulfinyl of 1 to 8 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, pyrrolidinyl, or thiazolidinyl;
- R11-R12 are independently H, straight chain alkyl of 1 to 8 carbon atoms, branched alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, a substituted or unsubstituted aryl or heteroaryl;
- Y is a bond, CH2, CH2CH2, aryl, or R2 and Y together with the ring carbon atom to which they are attached may additionally form a spirocyclic cycloalkyl ring of 3 to 8 carbon atoms;
- or
- a crystalline form or a pharmaceutically acceptable salt thereof.
A method of treating or preventing a Hepatitis C viral infection in a mammal comprising providing the mammal with an effective amount of a compound of a formula:
- 23
- wherein:
- R1 is H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl of 7 to 12 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, or heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, phenylalkynyl, an alkoxy of 1 to 6 carbon atoms, an arylalkoxy of 7 to 12 carbon atoms, a fluoroalkoxy of 1 to 12 carbon atoms, an alkylthio of 1 to 6 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, an acyl of 1 to 6 carbon atoms, a carboxy group, CONR11 R12, F, Cl, Br, I, CN, CF3, NO2, an alkylsulfinyl of 1 to 6 carbon atoms, an alkylsulfonyl of 1 to 6 carbon atoms;
- R11-R12 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups;
- Y is CH2, CH2CH2, or aryl;
- or
- a crystalline form or a pharmaceutically acceptable salt thereof.
A method of inhibiting replication of a Hepatitis C virus comprising contacting the Hepatitis C virus with a compound of a formula:
- 25
- wherein:
- R1 is H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl or an alkylaryl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl or alkylaryl of 7 to 12 carbon atoms, a cyanoalkyl of 1 to 8 carbon atoms, an alkylthioalkyl of 2 to 16 carbon atoms, a cycloalkyl-alkyl of 4 to 24 carbon atoms, a substituted or unsubstituted aryl, or a heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbons atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenylalkynyl, alkoxy of 1 to 8 carbon atoms, arylalkoxy of 7 to 12 carbon atoms, fluoroalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 8 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, acyl of 1 to 7 carbon atoms, COOH, COO-alkyl, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, alkylsulfinyl of 1 to 8 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, pyrrolidinyl, or thiazolidinyl;
- R11-R12 are independently H, straight chain alkyl of 1 to 8 carbon atoms, branched alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, a substituted or unsubstituted aryl or heteroaryl;
- Y is a bond, CH2, CH2CH2, aryl, or R2 and Y together with the ring carbon atom to which they are attached may additionally form a spirocyclic cycloalkyl ring of 3 to 8 carbon atoms;
- or
- a crystalline form or a pharmaceutically acceptable salt thereof.
A method of inhibiting replication of a Hepatitis C virus comprising contacting the Hepatitis C virus with a compound of a formula:
- 26
- R1 is H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl of 7 to 12 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, or heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, phenylalkynyl, an alkoxy of 1 to 6 carbon atoms, an arylalkoxy of 7 to 12 carbon atoms, a fluoroalkoxy of 1 to 12 carbon atoms, an alkylthio of 1 to 6 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, an acyl of 1 to 6 carbon atoms, a carboxy group, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, an alkylsulfinyl of 1 to 6 carbon atoms, an alkylsulfonyl of 1 to 6 carbon atoms;
- R11-R12 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups;
- Y is CH2, CH2CH2, or aryl;
- or
- a crystalline form or a pharmaceutically acceptable salt thereof.
A method of treating or preventing a Hepatitis C viral infection in a mammal comprising providing the mammal with an effective amount of at least one pharmaceutical composition, wherein the at least one pharmaceutical composition includes a compound of a formula:
- 28
- wherein:
- R1 is H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl or an alkylaryl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl or alkylaryl of 7 to 12 carbon atoms, a cyanoalkyl of 1 to 8 carbon atoms, an alkylthioalkyl of 2 to 16 carbon atoms, a cycloalkyl-alkyl of 4 to 24 carbon atoms, a substituted or unsubstituted aryl, or a heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbons atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenylalkynyl, alkoxy of 1 to 8 carbon atoms, arylalkoxy of 7 to 12 carbon atoms, fluoroalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 8 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, acyl of 1 to 7 carbon atoms, COOH, COO-alkyl, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, alkylsulfinyl of 1 to 8 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, pyrrolidinyl, or thiazolidinyl;
- R11-R12 are independently H, straight chain alkyl of 1 to 8 carbon atoms, branched alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, a substituted or unsubstituted aryl or heteroaryl;
- Y is a bond, CH2, CH2CH2, aryl, or R2 and Y together with the ring carbon atom to which they are attached form a spirocyclic cycloalkyl ring of 3 to 8 carbon atoms;
- and
- a pharmaceutically acceptable carrier.
A method of treating or preventing a Hepatitis C viral infection in a mammal comprising
- providing the mammal with an effective amount of at least one pharmaceutical composition, wherein the at least one pharmaceutical composition includes a compound of a formula:
- 29
- wherein:
- R1 is H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl of 7 to 12 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, or heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, phenylalkynyl, an alkoxy of 1 to 6 carbon atoms, an arylalkoxy of 7 to 12 carbon atoms, a fluoroalkoxy of 1 to 12 carbon atoms, an alkylthio of 1 to 6 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, an acyl of 1 to 7 carbon atoms, a carboxy group, CONR11R12, F, CI, Br, I, CN, CF3, NO2, an alkylsulfinyl of 1 to 6 carbon atoms, an alkylsulfonyl of 1 to 6 carbon atoms;
- R11-R12 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups;
- Y is CH2, CH2CH2, or aryl;
- and
- a pharmaceutically acceptable carrier.
A method of treating or preventing a Hepatitis C viral infection in a mammal comprising providing the mammal with an effective amount of at least one pharmaceutical composition, wherein the at least one pharmaceutical composition includes a compound of a formula
- 30
- wherein:
- R1 is H;
- R2 is H, or a straight chain alkyl of 1 to 4 carbon atoms;
- R3-R6 are H;
- R7-R10 are independently H, a straight chain alkyl of 1 to 3 carbon, F, Cl, or CN;
- Y is CH2;
- and
- a pharmaceutically acceptable carrier.
A method of inhibiting replication of a Hepatitis C virus comprising contacting the Hepatitis C virus with an effective amount of at least one pharmaceutical composition, wherein the at least one pharmaceutical composition includes a compound of a formula:
- 31
- wherein:
- R1 is H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl or an alkylaryl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl or alkylaryl of 7 to 12 carbon atoms, a cyanoalkyl of 1 to 8 carbon atoms, an alkylthioalkyl of 2 to 16 carbon atoms, a cycloalkyl-alkyl of 4 to 24 carbon atoms, a substituted or unsubstituted aryl, or a heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbon atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 8 carbon atoms, a branched alkyl of 3 to 12 carbons atoms, a cycloalkyl of 3 to 12 carbon atoms, an alkenyl of 2 to 7 carbon atoms, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, furanylmethyl, arylalkyl or alkylaryl of 7 to 12 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenylalkynyl, alkoxy of 1 to 8 carbon atoms, arylalkoxy of 7 to 12 carbon atoms, fluoroalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 8 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, acyl of 1 to 7 carbon atoms, COOH, COO-alkyl, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, alkylsulfinyl of 1 to 8 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, pyrrolidinyl, or thiazolidinyl;
- R11-R12 are independently H, straight chain alkyl of 1 to 8 carbon atoms, branched alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, a substituted or unsubstituted aryl or heteroaryl;
- Y is a bond, CH2, CH2CH2, aryl, or R2 and Y together with the ring carbon atom to which they are attached may additionally form a spirocyclic cycloalkyl ring of 3 to 8 carbon atoms;
- and
- a pharmaceutically acceptable carrier.
A method of inhibiting replication of a Hepatitis C virus comprising contacting the Hepatitis C virus with an effective amount of at least one pharmaceutical composition, wherein the at least one pharmaceutical composition includes a compound of a formula:
- 32
- wherein:
- R1 is H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or an arylalkyl of 7 to 12 carbon atoms;
- R2 is H, a straight chain alkyl of 1 to 12 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an alkynyl of 2 to 7 carbon atoms, an alkoxyalkyl of 2 to 12 carbon atoms, an arylalkyl of 7 to 12 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, or heteroaryl;
- R3-R6 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, or R5 and R6 together with the ring carbon atom to which they are attached form a carbonyl group;
- R7-R10 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbons atoms, a cycloalkyl of 3 to 10 carbon atoms, an alkenyl of 2 to 7 carbon atoms, an unsubstituted aryl or an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups, furanylmethyl, an arylalkyl of 7 to 12 carbon atoms, an alkynyl of 2 to 7 carbon atoms, phenylalkynyl, an alkoxy of 1 to 6 carbon atoms, an arylalkoxy of 7 to 12 carbon atoms, a fluoroalkoxy of 1 to 12 carbon atoms, an alkylthio of 1 to 6 carbon atoms, trifluoromethoxy, trifluoroethoxy, trifluoromethylthio, trifluoroethylthio, an acyl of 1 to 7 carbon atoms, a carboxy group, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, an alkylsulfinyl of 1 to 6 carbon atoms, an alkylsulfonyl of 1 to 6 carbon atoms;
- R11-R12 are independently H, a straight chain alkyl of 1 to 6 carbon atoms, a branched alkyl of 3 to 10 carbon atoms, a cycloalkyl of 3 to 10 carbon atoms, an aryl substituted with one to four groups, an unsubstituted heteroaryl or a heteroaryl substituted with one to three groups;
- Y is CH2, CH2CH2, or aryl;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.